Localization and effects of neuropeptide Y, vasoactive intestinal polypeptide, substance P, and calcitonin gene-related peptide in human temporal arteries.

Jansen I, Uddman R, Hocherman M, Ekman R, Jensen K, Olesen J, Stiernholm P, Edvinsson L

Annals of neurology1 Oct 1986Cited by 70 (Europe PMC)

PMID2431650DOI10.1002/ana.410200409PepBankPUB-02431650

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated human temporal artery segments, VIP potently relaxed vessels precontracted by prostaglandin F2 alpha.
In plain wordsIn lab tests on human temple artery tissue, VIP strongly relaxed vessels that were first made to contract.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseRelaxation of prostaglandin F2 alpha-precontracted temporal artery
Study
humann: not reported in source
isolated human temporal artery segments
Outcome group
Vascular function · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
VIP, peptide histidine methionine 27 (PHM-27), SP, neurokinin A (NKA), and CGRP potently relaxed vessels precontracted by prostaglandin F2 alpha, the relative potency being CGRP greater than SP greater than NKA = VIP = PHM-27.
Report a problemFND-0243165001

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

02LabEndogenous levelEx vivo tissueOther
In the human temporal artery, nerve fibers containing the body's own VIP were seen in the adventitia or at the adventitia-media border.
In plain wordsIn human temple artery tissue, nerve fibers holding the body's own VIP were found in the outer layers of the vessel wall.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableLocalization of VIP-containing nerve fibers in temporal artery
Study
humann: not reported in source
isolated human temporal artery segments
Outcome group
Endogenous peptide levels · Cardiovascular
Source sentences
Summary
Nerve fibers containing neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP), substance P (SP), and calcitonin gene-related peptide (CGRP) were seen in the adventitia or at the adventitia-media border of the human temporal artery.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0243165004

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueEfficacy outcome
In isolated human temporal artery segments, the pooled relaxant peptides (VIP, PHM-27, substance P, neurokinin A and CGRP) relaxed 67 to 91% of the prostaglandin F2 alpha-induced contraction.
In plain wordsIn lab tests on human temple artery tissue, the group of peptides tested, including VIP, relaxed most of the induced contraction.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseDegree of relaxation by pooled peptides
Study
humann: not reported in source
isolated human temporal artery segments
Outcome group
Vascular function · Cardiovascular
Measurements
Relaxation
67 to 91 % of prostaglandin F2 alpha-induced contraction
pooled peptides
Source sentences
Summary
The amount of relaxation varied between 67 and 91% of the prostaglandin F2 alpha-induced contraction.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0243165002
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneEx vivo tissueMechanism
In isolated human temporal artery segments, the relaxant effects of the tested peptides, including VIP, were not antagonized by classic adrenergic or cholinergic blockers.
In plain wordsIn lab tests on human temple artery tissue, the relaxing effects of the peptides tested, including VIP, were not blocked by standard blockers.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeAntagonism of peptide relaxation by adrenergic or cholinergic blockers
Study
humann: not reported in source
isolated human temporal artery segments
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
The peptide effects were not antagonized by classic adrenergic or cholinergic blockers, suggesting interactions via separate receptor sites.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0243165003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.